<code id='23657833A8'></code><style id='23657833A8'></style>
    • <acronym id='23657833A8'></acronym>
      <center id='23657833A8'><center id='23657833A8'><tfoot id='23657833A8'></tfoot></center><abbr id='23657833A8'><dir id='23657833A8'><tfoot id='23657833A8'></tfoot><noframes id='23657833A8'>

    • <optgroup id='23657833A8'><strike id='23657833A8'><sup id='23657833A8'></sup></strike><code id='23657833A8'></code></optgroup>
        1. <b id='23657833A8'><label id='23657833A8'><select id='23657833A8'><dt id='23657833A8'><span id='23657833A8'></span></dt></select></label></b><u id='23657833A8'></u>
          <i id='23657833A8'><strike id='23657833A8'><tt id='23657833A8'><pre id='23657833A8'></pre></tt></strike></i>

          fashion

          fashion

          author:explore    Page View:3758
          Micky Tripathi Office of the National Coordinator for Health Information Technology

          Micky Tripathi is equal parts excited — and deeply concerned — about the technological change sweeping through medicine.

          As adoption of generative AI races ahead,  his job as National Coordinator for Health Information Technology under President Joe Biden is to manage this change, and keep it safe and organized. But how do you organize a pell-mell rush? How do you keep chaos safe?

          advertisement

          “It’s definitely changed my life,” Tripathi said of his official remit, which also led to his appointment as co-chair of a task force on AI within the Department of Health and Human Services.  “We believe it’s really, really important that we be out ahead of this.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          Startup Neumora takes a novel depression drug to Phase 3
          Startup Neumora takes a novel depression drug to Phase 3

          AdobeNeumora,aprivatelyheldbiotechcompany,ismovingintothefinalphaseoftestingwithanoveltreatmentforde

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          STAT Virtual Event: The State of Biosimilars: What to Watch

          Editor’snote:Arecordingoftheeventisembeddedbelow.NowthatbiosimilarversionsofHumiraarestartingtoarriv